On December 4, Robert F. Kennedy, Jr. sent a letter to Peter Marks, Director of the Center for Biologics Evaluation and Research’s (CBER), on behalf of Children’s Health Defense (CHD) asking the Food and Drug Administration (FDA) to take a cautious approach in approving COVID-19 vaccines that have been developed at “warp speed.” Considering that almost $4.5 billion has been paid out to vaccine injured individuals from vaccines developed in traditional timelines, caution, and concern for human safety should be the FDA’s top priority in the approval process.

This coming Thursday, December 10, CBER’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 in individuals 16 years of age and older. CHD asks that you take the following steps to urge VRBPAC to make safety the chief concern in its considerations:



Read more…